stocktwits
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside
Shares of Outlook Therapeutics, Inc. (OTLK) rallied 12% overnight heading into Monday after the FDA approved Lytenava, the company’s eye drug for treating wet age-related macular degeneration (wet AMD), removing a major regulatory hurdle and putting the spotlight on how much value it can capture as…